Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Days Sales Outstanding for the
three
months ended in Jun. 2026 was 96.45.
In Ben Graham's calculation of liquidation value, Apple Inc's Accounts Receivable are only considered to be worth 75% of book value. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's liquidation value for the
three
months ended in Jun. 2026 was ₺711 Mil.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) Change In Receivables Explanation
1. Accounts Receivable are created when a customer has received a product but has not yet paid for that product. Days Sales Outstanding measures of the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Days Sales Outstanding for the quarter that ended in Jun. 2026 is calculated as:
2. In Ben Graham's calculation of liquidation value, MEDITERA TIBBI MALZEMENAYI VE TICARET AS's accounts receivable are only considered to be worth 75% of book value:
MEDITERA TIBBI MALZEMENAYI VE TICARET AS's liquidation value for the quarter that ended in Jun. 2026 is calculated as:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS Change In Receivables Related Terms
MEDITERA TIBBI MALZEMENAYI VE TICARET AS Change In Receivables Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
MEDITERA TIBBI MALZEMENAYI VE TICARET AS Change In Receivables Chart
MEDITERA TIBBI MALZEMENAYI VE TICARET AS Annual Data
MEDITERA TIBBI MALZEMENAYI VE TICARET AS Change In Receivables Calculation
Change In Accounts Receivable relative to the previous period. It is any increase or decrease in the cash a company is owed by its customers.
Change In Receivables for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was ₺235 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Change In Receivables of ₺235 Mil mean?
MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) has a Change In Receivables of ₺235 Mil as of Jun. 2026. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for MEDITERA TIBBI MALZEMENAYI VE TICARET AS and its competitors.
Is MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Change In Receivables too high?
MEDITERA TIBBI MALZEMENAYI VE TICARET AS's current Change In Receivables is ₺235 Mil. Overall, MEDITERA TIBBI MALZEMENAYI VE TICARET AS has a GF Score™ of 80/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Change In Receivables compare to ABT and SYK?
MEDITERA TIBBI MALZEMENAYI VE TICARET AS's Change In Receivables of ₺235 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Change In Receivables for a Medical Devices & Instruments company?
A good Change In Receivables depends on the Medical Devices & Instruments industry context. However, Change In Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Change In Receivables mean?
A high Change In Receivables can signal that a stock is expensive relative to its fundamentals. Change in Receivables is the difference between current-period receivables and past-period receivables. View historical data for MEDITERA TIBBI MALZEMENAYI VE TICARET AS and its competitors. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's current Change In Receivables is ₺235 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is MEDITERA TIBBI MALZEMENAYI VE TICARET AS stock overvalued right now?
Based on GuruFocus' analysis, MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) is currently considered Significantly Undervalued. The stock's GF Value™ is ₺39.85, compared to a current price of ₺23.94 — trading 39.9% below its estimated fair value. The current Change In Receivables is ₺235 Mil. MEDITERA TIBBI MALZEMENAYI VE TICARET AS's overall GF Score™ is 80/100 with 5 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Change In Receivables calculated?
Change In Receivables is calculated from a company's financial statements. For MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR), the current Change In Receivables is ₺235 Mil as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is MEDITERA TIBBI MALZEMENAYI VE TICARET AS (IST:MEDTR) Overvalued in 2026?
Based on GuruFocus' analysis, MEDITERA TIBBI MALZEMENAYI VE TICARET AS stock appears to be undervalued.
The current stock price of ₺23.94 is trading 39.9% below its estimated GF Value™ of ₺39.85.
GuruFocus considers MEDITERA TIBBI MALZEMENAYI VE TICARET AS to be Significantly Undervalued.
Key valuation signals for IST:MEDTR:
Change In Receivables: ₺235 Mil
GF Value™: ₺39.85 vs. price of ₺23.94 (39.9% below fair value)
No single metric tells the full story. See the IST:MEDTR stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
MEDITERA TIBBI MALZEME SANAYI VE TICARET AS is engaged in the manufacture of anesthesia and intensive care circuits, the installation, operation, and design of oncology drug preparation and delivery systems, production, sales, and technical service of infusion pumps and sets, and the manufacture of biocidal products.
80GF Score
Get the complete analysis for IST:MEDTR
Change In Receivables is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
IST:MEDTR has been successfully added to your 
